bioMerieux : Q2 2020 sales still brisk and in line with our expectations - full-year forecasts adjusted (+5%e) – target price: € 117 vs € 113 - Neutral vs Buy
>Pre-announcement of Q2 2020 sales: broadly in line - Q2 2020 sales totalled and estimated € 707m. As in Q1, growth is clearly driven by molecular biology (+62% vs +70% estimated) which currently represents 37% of sales (vs 25% in 2019).At end-June, growth reached +15.8% and 15.7% at constant currency, i.e. € 1,476m est. (vs € 1,466m est).The details of Q2 2020 sales and the H1 2020 financial results are due to be published on 2 September 2020. Lastly, ...Co. specializes in the field of in vitro diagnostics for clinical and industrial applications. Co. designs, develops, manufactures and markets systems used in: Clinical Applications (the diagnosis of infectious diseases such as hepatitis, HIV, tuberculosis and respiratory illnesses, as well as pathologies such as cardiovascular diseases and cancers, based on the analysis of biological samples such as blood, saliva or urine); and Industrial Applications (microbiological analysis of samples of finished or semi-finished products (or of the environment), chiefly in the food processing and biopharmaceutical industries), detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.